Published in March 2015
In order to assess the efficacy of ivabradine in chronic heart failure patients with angina, an analysis was carried out for this subgroup from the SHIFT study (2220 patients [34%] had a history of angina at baseline).1
In those patients, the SHIFT primary end point, cardiovascular death or hospitalization for worsening heart failure was reduced by 15% (P=0.0553). This confirmed ivabradine’s efficacy in reducing cardiovascular death or hospitalization for worsening heart failure in patients with chronic heart failure with or without angina.

1. Borer JS et al. Efficacy profile of ivabradine in patients with heart failure plus angina pectoris . J Am Coll Cardiol. 2015;65(10_S):A791. Oral contributions.